Bioidentical Hormones - U.S. Senate Special Committee on Aging

More documents

Recommendations

Info

Women's Health Initiative Main Results Trial of Estrogen plus Progestin - Ended early after 5+F years - Increased breast cancer, heart disease, stroke, blood clots, dementia - Reduced fractures, colorectal cancer * Trial of Estrogen-only - Ended early after 7 years - Increased stroke, blood clots, dementia - No effect on heart disease, cancer - Reduced fractures
Hormone Therapy after WHI * Change in recommendations to "Do not use hormone therapy to prevent heart disease" * Black box warning on package insert * Large drop in hormone prescriptions N) - Approx. 21 million women given prescriptions in 2001 - Approx. 6 million women in 2006 * Proven uses * Treatment of hot flashes, night sweats, vaginal atrophy (low dose, short time, prefer local) * Prevention of osteoporosis (prefer other therapies)
Page 1 and 2:
S. HRG. 110-129 Bioidentica
Page 3 and 4:
CONTENTS Page Opening Statement of
Page 5 and 6:
2 The sale of bioidentical hormone
Page 7 and 8:
4 ever, as Dr. Wartofsky points out
Page 9 and 10:
6 with every stage of the disease:
Page 11 and 12:
8 I am pleased to appear before thi
Page 13 and 14:
10 When the trials began, many rese
Page 15 and 16:
Women who began treatment more than
Page 17 and 18:
14 One small trial using oral estra
Page 19 and 20:
16 FDA is aware that a growing numb
Page 21 and 22:
18 DEPARTMENT OF HEALTH & HUMAN SER
Page 23 and 24:
20 safety and efficacy. However, as
Page 25 and 26:
22 adulteration and misbranding pro
Page 27 and 28:
24 The 2002 CPG reflects FDA's curr
Page 29 and 30:
26 Equally concerning are claims by
Page 31 and 32:
28 concerned about the use and mark
Page 33 and 34:
30 Part I: Materials and Partnershi
Page 35 and 36:
32 drugs, when the compounding of t
Page 37 and 38:
34 Our staff identified 34 Web site
Page 39 and 40:
1. Introduction 36 Chairman Kohl, R
Page 41 and 42:
diet and fitness products. 5 For ex
Page 43 and 44:
include "natural" progesterone crea
Page 45 and 46:
42 unique to the computer age, such
Page 47 and 48:
computer users to spam(ftuce.0ov -
Page 49 and 50:
46 accuracy of advertising for heal
Page 51 and 52:
48 Now, you have identified in your
Page 53 and 54:
50 claim." Therefore, since the ter
Page 55 and 56:
52 Such quality control problems ha
Page 57 and 58:
54 Statement Before the U.S. <stron
Page 59 and 60:
in the U.S., whereas WHI participan
Page 61 and 62:
58 between science and hearsay and
Page 63 and 64:
60 How can we determine whether bio
Page 65 and 66:
62 doctors-are not getting the obje
Page 67 and 68:
64 27. Writing Group for the PEPI T
Page 69 and 70:
66 Dr. MANSON. Well, I think that m
Page 71 and 72:
68 Statement of Leonard Wartofsky,
Page 73 and 74:
70 in the WHI. In fact, no study as
Page 75 and 76:
In summary, the Endocrine Society i
Page 77 and 78:
74 The FDA also regulates aspects o
Page 79 and 80:
Statement of Loyd V. Allen, Jr., Ph
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
82 Senator SMITH. Dr. Allen, as I h
Page 87 and 88:
84 Now, when you are talking about
Page 89 and 90:
86 The only thing the WHI proved wa
Page 91 and 92:
88 Testimony Of T.S. Wiley before t
Page 93 and 94:
Confusion and Media Hype 90 Instead
Page 95 and 96:
92 see a doctor tell a diabetic nea
Page 97 and 98:
94 the only compelling reason to ta
Page 99 and 100:
96 identical hormones synthesized f
Page 101 and 102:
98 The world as we know it, from ba
Page 103 and 104:
100 thereby experienced long period
Page 105 and 106:
102 Bio-identical progesterone repl
Page 107 and 108:
104 had reached optimum theoretical
Page 109 and 110:
106 and the patient can be can reas
Page 111 and 112:
108 Estradiol and Analytical Resear
Page 113 and 114:
110 A controlled systematic pilot c
Page 115 and 116:
112 of set doses. The Wiley Protoco
Page 117 and 118:
114 I'd advocate for either Accredi
Page 119 and 120:
116 D.C., and established a goal to
Page 121 and 122:
118 If this legislation passes, fed
Page 123 and 124:
first and second finger on the barr
Page 125 and 126:
122 These products that have been s
Page 127 and 128:
124 Bcl-2, survivin and variant CD4
Page 129 and 130:
126 These are experiments by other
Page 131 and 132:
128 cerebro-cellular inflammation c
Page 133 and 134:
130 Years # women *1>0.5 8 *1+ 9 *2
Page 135 and 136:
*Breast cancer 132 -57 y.o. recurre
Page 137 and 138:
134 *Labor intense for patient and
Page 139 and 140:
136 Senator SMITH. Thank you very m
Page 141 and 142:
138 makes these hormones uniquely s
Page 143 and 144:
140 tomize the Wiley Protocol by ra
Page 145 and 146:
142 "natural," because all lead to
Page 147 and 148:
144 maceutical commerce, often with
Page 149 and 150:
146 WHITE PAPER #1 DID YOU KNOW THA
Page 151 and 152:
148 WHITE PAPER #2 Pharmacy Compoun
Page 153 and 154:
150 bleeding of the bowel, locate t
Page 155 and 156:
152 compounding standards can be en
Page 157 and 158:
154 I. The FDA's definition of a "N
Page 159 and 160:
156 ORIIGINAL CONTrMIBTION JANMA-EX
Page 161 and 162:
Initially, the design allowed women
Page 163 and 164:
ards analyses," stratified by clini
Page 165 and 166:
year). These 'drop-in" rates were a
Page 167 and 168:
years of prior use, 11 vs 2; HR, 4.
Page 169 and 170:
trogen plus progestin exposure. Clo
Page 171 and 172:
168 RISKS AND BENEFITS OF ESTROGEN
Page 173 and 174:
EFFECTS OF POSTMENOPAUSAL ESTIROGEN
Page 175 and 176:
EFFECTS OF POSTMENOPAUSAL ESTROGEN
Page 177 and 178:
EFFECTS OF POSTMENOPAUSAL ESTROGEN
Page 179 and 180: pEyECTS OF POSTMENOPAUSAL ESTROGEN
Page 181 and 182: EFFECTS OF POSTMENOPAUSAL ESTROGEN
Page 183 and 184: EFFECTS OF POSTMENOPAUSAL ESTROGEN
Page 185 and 186: 10000 isoor i I ea '° a wan 20-24
Page 187 and 188: ~SDt~rpa g~2~Q ~ !~fm~. b~e ~ ng jh
Page 189 and 190: Is associated with an Increased ris
Page 191 and 192: 188 Postmenopausal hormone therapy
Page 193 and 194: group (P= 04001), and In this subgr
Page 195 and 196: Treatmnent recommendations Based on
Page 197 and 198: 21.Grodsteln F. Manson JE, Colditz
Page 199 and 200: _ ORWIGNAL CONTIuBUTION 196 Postmen
Page 201 and 202: showed no striking differences in H
Page 203 and 204: (214 cases; P for trend=.72): howev
Page 205 and 206: 202 HORMONE THERAPY USE AND RISK OF
Page 207 and 208: mal studies, and laboratory studies
Page 213 and 214: 210 ,lmcCII na: CLI I tr: tarty ver
Page 215 and 216: 212 ,mucmai rimi &ronos farty bstro
Page 217 and 218: 214 LntIucwu miau: rronos nary estr
Page 219 and 220: XVI. PNharmacy Licensure Requiremen
Page 221 and 222: XVI. Pharmacy Licensure Requirement
Page 223 and 224: 220 Roster of Board of Pharmacy Ece
Page 225 and 226: 050. 0l7404405400 Al-h. PeVbU 03283
Page 227 and 228: Conclusions * Age is a powerful ris
Page 229: Women's Health Initiative Trials of
Page 233 and 234: Statement of the American Pharmacis
Page 235 and 236: 232 APhA Statement to the S
Page 243 and 244: 240 Written Testimony of Steven F.
Page 245 and 246: 242 STATEMENT OF DAVID G. ADAMS On
Page 247 and 248: 244 Report on State Laws and Regula
Page 249 and 250: 246 Only one state, Utah, requires
Page 251: 248 5. Compounding Copies of FDA-Ap
show all

Bioidentical Hormones - U.S. Senate Special Committee on Aging

Create successful ePaper yourself

Delete template?

Save as template?